Abstract: Alzheimer’s disease (AD) and AD-related dementias (ADRD) represent a significant health challenge, with a growing impact on marginalized populations who often experience inequities in overall healthcare access and outcomes. Many factors contribute to these inequalities and can impact the benefits of a broad appreciation of new technologies in AD/ADRD for these populations. For example, clinical proteomics offers a promising avenue for the early and timely detection of disease and the elucidation of the mechanisms underlying AD/ADRD.
Unfortunately, gaps exist in the access and application of proteomic innovations for the health of marginalized communities.
This editorial:
(1) highlights systemic barriers and explores the underlying factors that contribute to these inequities
(2) examines health disparities in the implementation of clinical proteomics tools for the management of AD/ADRD among marginalized populations, and
(3) offers opportunities for advancing clinical proteomics in AD/ADRD. Implementation by basic and clinical researchers will lead to a more effective and inclusive approach to combating AD/ADRD disparities.
Get the full insights here: Bridging Health Disparity Gaps in Alzheimer’s Disease among Marginalized Populations: Clinical Proteomics as a Case Study | ACS Bio & Med Chem Au
